looking at aneuploidy rates in embryos from patients who are going to or have undergone treatment for a malignancy with gonadotoxic treatment.

The study involves oncofertility patients--individuals who are undergoing or have undergone therapy for a malignancy--who are interested in pursuing or preserving fertility. In particular, it investigates chromosomal abnormalities or aneuploidy in the embryos of those individuals as compared to the general infertility population. Embryonic aneuploidy is largely due to reproductive senescence. As such the investigators will discuss oncofertility prevalence and treatment as well as reproductive senescence and assessment of embryonic aneuploidy. The study will seek to determine if there are changes in embryonic aneuploidy rates in oncofertility patients that differ from simple age related risks.

Inclusion Criteria:

1.Present or past oncologic diagnosis requiring potentially gonadotoxic treatment

Exclusion Criteria:

1. Oocyte banking
2. Use of oocyte donation
3. Any contraindications to undergoing in vitro fertilization or gonadotropin stimulation
4. Single gene disorder requiring more detailed embryo genetic analysis

oncofertility patient undergoing controlled ovarian hyperstimulation and embryo cryopreservation